KSHV and EBV are gammaherpesviruses strictly linked to human cancers. Even if the majority of cancer cells harbor a latent infection, the few cells that undergo viral replication may contribute to the pathogenesis and maintenance of the virus-associated malignancies. Cytotoxic drugs used for the therapies of cancers harboring virus-infection often have, as side effect, the activation of viral lytic cycle. Therefore it is important to investigate whether they affect viral reactivation and understand the underlying mechanisms involved. In this study, we found that proteasome inhibitor bortezomib, a cytotoxic drug that efficiently target gammaherpesvirus-associated B cell lymphomas, triggered KSHV or EBV viral lytic cycle by activating JNK, in the course of ER stress, and inducing autophagy. These results suggest that the manipulation of these pathways could limit viral spread and improve the outcome of bortezomib treatment in patients affected by gammaherpesvirus-associated lymphomas.
Bortezomib promotes KHSV and EBV lytic cycle by activating JNK and autophagy / Granato, Marisa; Romeo, Maria Anele; Tiano, Mariangela Sara; Santarelli, Roberta; Gonnella, Roberta; Gilardini Montani, Maria Saveria; Faggioni, Alberto; Cirone, Mara. - In: SCIENTIFIC REPORTS. - ISSN 2045-2322. - ELETTRONICO. - 7:1(2017). [10.1038/s41598-017-13533-7]
Bortezomib promotes KHSV and EBV lytic cycle by activating JNK and autophagy
Granato, Marisa;Romeo, Maria Anele;Santarelli, Roberta;Gonnella, Roberta;Gilardini Montani, Maria Saveria;Faggioni, Alberto;Cirone, Mara
2017
Abstract
KSHV and EBV are gammaherpesviruses strictly linked to human cancers. Even if the majority of cancer cells harbor a latent infection, the few cells that undergo viral replication may contribute to the pathogenesis and maintenance of the virus-associated malignancies. Cytotoxic drugs used for the therapies of cancers harboring virus-infection often have, as side effect, the activation of viral lytic cycle. Therefore it is important to investigate whether they affect viral reactivation and understand the underlying mechanisms involved. In this study, we found that proteasome inhibitor bortezomib, a cytotoxic drug that efficiently target gammaherpesvirus-associated B cell lymphomas, triggered KSHV or EBV viral lytic cycle by activating JNK, in the course of ER stress, and inducing autophagy. These results suggest that the manipulation of these pathways could limit viral spread and improve the outcome of bortezomib treatment in patients affected by gammaherpesvirus-associated lymphomas.File | Dimensione | Formato | |
---|---|---|---|
Granato_Bortezomib-promotes_2017.pdf
accesso aperto
Tipologia:
Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza:
Creative commons
Dimensione
3.19 MB
Formato
Adobe PDF
|
3.19 MB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.